99 Wall Street, Suite 232, New York, NY 10005

需要帮忙?呼叫(800) 991-3756

Class Action Cases

A class action has been filed on behalf of GOSS Investors. Click "Join this Class Action" above.

Attorneys

(English) Gossamer Bio, Inc.

Join Class Action »

对不起,此内容只适用于美式英文

Press Release

(English) SHAREHOLDER ALERT: Zhang Investor Law Announces a Securities Class Action Lawsuit Against Gossamer Bio, Inc. – GOSS

New York, N.Y., April 7, 2020. Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Gossamer Bio, Inc. (NASDAQ: GOSS) (i) pursuant and/or traceable to the Company’s initial public offering in February 2019 (the “IPO” or “Offering”); and/or (ii) between February 8, 2019 and December 13, 2019, inclusive (the “Class Period”).

To join the GOSS class action, go to http://zhanginvestorlaw.com/cases/gossamer-bio-inc/ call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT.  YOU NEED NOT BE A LEAD PLAINTIFF TO OBTAIN A RECOVERY.

According to the lawsuit, throughout the Class Period the materials supporting the Offering, and certain of Gossamer’s post-IPO public filings, may have misled investors or otherwise omitted material facts relevant to Gossamer’s GB001 drug and its related clinical trials and studies. Then, on December 16, 2019, Novartis announced that it was terminating the development of its DP2 antagonist for asthma after it failed a pair of phase 3 clinical trials. As a result, Gossamer’s common stock dropped by approximately 37% in one day. The stock has continued to plummet, and is presently trading around $10.00 per share. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 2, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/gossamer-bio-inc/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at info@zhanginvestorlaw.com.

Zhang Investor Law represents investors worldwide.